Tarsus Pharmaceuticals (TARS) EBIAT (2020 - 2025)
Historic EBIAT for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to -$12.6 million.
- Tarsus Pharmaceuticals' EBIAT rose 4626.39% to -$12.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$81.2 million, marking a year-over-year increase of 3958.9%. This contributed to the annual value of -$115.6 million for FY2024, which is 1496.69% up from last year.
- Tarsus Pharmaceuticals' EBIAT amounted to -$12.6 million in Q3 2025, which was up 4626.39% from -$20.3 million recorded in Q2 2025.
- In the past 5 years, Tarsus Pharmaceuticals' EBIAT ranged from a high of $10.4 million in Q1 2021 and a low of -$41.9 million during Q4 2023
- In the last 5 years, Tarsus Pharmaceuticals' EBIAT had a median value of -$22.5 million in 2022 and averaged -$20.3 million.
- As far as peak fluctuations go, Tarsus Pharmaceuticals' EBIAT soared by 63019.93% in 2021, and later crashed by 44717.05% in 2023.
- Tarsus Pharmaceuticals' EBIAT (Quarter) stood at -$14.9 million in 2021, then grew by 8.43% to -$13.6 million in 2022, then crashed by 208.13% to -$41.9 million in 2023, then soared by 44.84% to -$23.1 million in 2024, then surged by 45.55% to -$12.6 million in 2025.
- Its last three reported values are -$12.6 million in Q3 2025, -$20.3 million for Q2 2025, and -$25.1 million during Q1 2025.